- Conditions
- Lymphoma
- Interventions
- cyclophosphamide, etoposide, BCNU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2010
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 193
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, temozolomide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
- Conditions
- CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Methotrexate, Rituximab, Tacrolimus
- Procedure · Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- 75 approved agents, COXEN
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 22
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Loncastuximab Tesirine, Melphalan
- Procedure · Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- filgrastim, carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, mitoxantrone hydrochloride, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Newly Diagnosed Supratentorial Malignant Glioma
- Interventions
- Gliadel Wafer, Temozolomide, Limited field radiation
- Drug · Procedure
- Lead sponsor
- Kentuckiana Cancer Institute
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Indolent Non-Hodgkin Lymphoma
- Interventions
- Carmustine, Cytarabine, Etoposide, Hematopoietic Cell Transplantation, Melphalan, Venetoclax
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- VI-0609, BiCNU
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Goodyear, Arizona • Duarte, California • Newnan, Georgia + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
- Conditions
- Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
- Interventions
- Electric Field Therapy, Bevacizumab, Carmustine, Quality-of-Life Assessment
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 22 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Sacramento, California • Atlanta, Georgia
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glioma
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Kentuckiana Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Rituximab, Umbilical Cord Blood-derived Natural Killer Cells
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- B-Cell Lymphoma Originating in the CNS
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Infection, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glioblastoma
- Interventions
- Edotecarin, Temozolomide, Carmustine (BCNU), Lomustine (CCNU)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 16 more
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Neuroblastoma, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Regional Neuroblastoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- etoposide, cyclophosphamide, carmustine, melphalan, busulfan, carboplatin, thiotepa, total-body irradiation, autologous hematopoietic stem cell transplantation, autologous-autologous tandem hematopoietic stem cell transplantation
- Drug · Radiation · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York